Andrew D J Pearson

Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Derek Stephens, Barbara Hero, Samuel L Volchenboum, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Sergey Popov, Dow-Mu Koh, Chris Jones, 2013, Radiology.

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Barbara Hero, Andreas Faldum, David Machin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Giovanni Cecchetto, Peter F Ambros, H. Brisse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How can attrition rates be reduced in cancer drug discovery?

Andrew D J Pearson, A. Pearson, L. Moreno, 2013, Expert opinion on drug discovery.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Gudrun Schleiermacher, Hubert Caron, Birgit Geoerger, 2016, European journal of cancer.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Bandana Sharma, Wenchao Wang, Nathanael S Gray, 2012, Cancer cell.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Gudrun Schleiermacher, Frank Berthold, Samuel L Volchenboum, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.